Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN44218911
ISRCTN44218911
Completed
Not Applicable

A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose-ranging pilot study of ethyl-eicosapentaenoate (ethyl-EPA) in patients with schizophrenia

axdale Ltd (UK)0 sites0 target enrollmentJuly 1, 2001
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsSchizophreniaMental and Behavioural Disorders

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
axdale Ltd (UK)
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 1, 2001
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
axdale Ltd (UK)

Eligibility Criteria

Inclusion Criteria

  • •1\. Written informed consent
  • •2\. Diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM\-IV) criteria
  • •3\. Minimum duration of 12 weeks from diagnosis
  • •4\. Maximum duration of 20 years from diagnosis
  • •5\. Maintained on same neuroleptic drug(s) for 12 weeks and on the same dose for 4 weeks
  • •6\. Total Positive and Negative Syndrome Scale (PANSS) score of 50 or more and a positive sub\-scale PANSS score of 15 or more
  • •7\. Aged 18 \- 65 of either sex
  • •8\. In\-patient or out\-patient

Exclusion Criteria

  • •Not provided at time of registration

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) in patients with a new or recurrent episode of depressioDepressionMental and Behavioural DisordersDepressive episode
ISRCTN63565713axdale Ltd (UK)
Completed
Not Applicable
A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose ranging pilot study of ethyl eicosapentaenoate (EPA) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapyDepressionMental and Behavioural Disorders
ISRCTN44366049axdale Ltd (UK)
Completed
Not Applicable
A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapyDepressionMental and Behavioural DisordersDepressive episode
ISRCTN38354847axdale Ltd (UK)
Active, not recruiting
Not Applicable
Clinical study to investigate the efficacy and safety of an ointment that increases the blood circulation in the skin, containing 2.5% Nicoboxil and 0.4% Nonivamide, in comparison to ointments that contain only one of both compounds, or none of them (placebo) for the treatment of acute low back paiAcute low back painTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2011-003890-27-DEBoehringer Ingelheim Pharma GmbH & Co. KG
Active, not recruiting
Phase 1
Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthma
EUCTR2013-002345-11-GBAstraZeneca AB1,134